Aileron Therapeutics (ALRN) Competitors $1.75 -0.01 (-0.57%) (As of 12/20/2024 05:15 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends ALRN vs. KYTX, MDWD, DRUG, CRBP, IPHA, ACTU, STRO, SGMT, CRBU, and TSVTShould you be buying Aileron Therapeutics stock or one of its competitors? The main competitors of Aileron Therapeutics include Kyverna Therapeutics (KYTX), MediWound (MDWD), Bright Minds Biosciences (DRUG), Corbus Pharmaceuticals (CRBP), Innate Pharma (IPHA), Actuate Therapeutics (ACTU), Sutro Biopharma (STRO), Sagimet Biosciences (SGMT), Caribou Biosciences (CRBU), and 2seventy bio (TSVT). These companies are all part of the "pharmaceutical products" industry. Aileron Therapeutics vs. Kyverna Therapeutics MediWound Bright Minds Biosciences Corbus Pharmaceuticals Innate Pharma Actuate Therapeutics Sutro Biopharma Sagimet Biosciences Caribou Biosciences 2seventy bio Kyverna Therapeutics (NASDAQ:KYTX) and Aileron Therapeutics (NASDAQ:ALRN) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, media sentiment, earnings, community ranking, valuation, risk and analyst recommendations. Do institutionals and insiders believe in KYTX or ALRN? 18.1% of Kyverna Therapeutics shares are held by institutional investors. Comparatively, 90.9% of Aileron Therapeutics shares are held by institutional investors. 5.1% of Aileron Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Does the MarketBeat Community believe in KYTX or ALRN? Aileron Therapeutics received 203 more outperform votes than Kyverna Therapeutics when rated by MarketBeat users. Likewise, 66.98% of users gave Aileron Therapeutics an outperform vote while only 66.67% of users gave Kyverna Therapeutics an outperform vote. CompanyUnderperformOutperformKyverna TherapeuticsOutperform Votes1066.67% Underperform Votes533.33% Aileron TherapeuticsOutperform Votes21366.98% Underperform Votes10533.02% Does the media favor KYTX or ALRN? In the previous week, Kyverna Therapeutics had 38 more articles in the media than Aileron Therapeutics. MarketBeat recorded 38 mentions for Kyverna Therapeutics and 0 mentions for Aileron Therapeutics. Kyverna Therapeutics' average media sentiment score of 0.10 beat Aileron Therapeutics' score of 0.00 indicating that Kyverna Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Kyverna Therapeutics Neutral Aileron Therapeutics Neutral Do analysts recommend KYTX or ALRN? Kyverna Therapeutics currently has a consensus price target of $25.71, suggesting a potential upside of 542.86%. Aileron Therapeutics has a consensus price target of $19.00, suggesting a potential upside of 985.71%. Given Aileron Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Aileron Therapeutics is more favorable than Kyverna Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kyverna Therapeutics 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.00Aileron Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50 Is KYTX or ALRN more profitable? Kyverna Therapeutics' return on equity of -51.12% beat Aileron Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Kyverna TherapeuticsN/A -51.12% -37.91% Aileron Therapeutics N/A -74.08%-27.93% Which has preferable valuation and earnings, KYTX or ALRN? Aileron Therapeutics has lower revenue, but higher earnings than Kyverna Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKyverna Therapeutics$7.03M24.56-$60.37MN/AN/AAileron TherapeuticsN/AN/A-$15.73M-$3.12-0.56 SummaryAileron Therapeutics beats Kyverna Therapeutics on 8 of the 13 factors compared between the two stocks. Ad Behind the MarketsWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Click to get the name and ticker symbol Get Aileron Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ALRN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALRN vs. The Competition Export to ExcelMetricAileron TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$37.92M$6.57B$5.14B$9.08BDividend YieldN/A3.00%5.09%4.23%P/E Ratio-0.5610.5989.9717.18Price / SalesN/A195.801,116.21116.99Price / CashN/A57.1642.8937.86Price / Book1.245.094.784.78Net Income-$15.73M$151.83M$120.23M$225.60M7 Day Performance-22.57%-2.13%-1.92%-1.23%1 Month Performance-32.17%-3.10%11.49%3.36%1 Year Performance-41.86%11.54%30.57%16.60% Aileron Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALRNAileron Therapeutics3.0723 of 5 stars$1.75-0.6%$19.00+985.7%-43.5%$37.92MN/A-0.569Positive NewsKYTXKyverna Therapeutics2.4246 of 5 stars$4.30-2.7%$25.71+498.0%N/A$185.64M$7.03M0.0096News CoverageMDWDMediWound1.9106 of 5 stars$17.04-1.4%$27.50+61.4%+58.3%$183.79M$19.72M-5.9380Positive NewsGap DownDRUGBright Minds Biosciences3.5821 of 5 stars$40.82-0.4%$75.00+83.7%+2,621.8%$181.00MN/A-60.29N/ANews CoverageCRBPCorbus Pharmaceuticals3.8067 of 5 stars$14.52-3.7%$62.00+327.0%+147.6%$176.85M$880,000.00-3.2240IPHAInnate Pharma2.7604 of 5 stars$2.18-27.8%$11.50+427.2%-23.5%$176.63M$24.85M0.00220News CoverageGap DownHigh Trading VolumeACTUActuate TherapeuticsN/A$8.86+2.8%N/AN/A$173.05MN/A0.0010Gap UpSTROSutro Biopharma4.4638 of 5 stars$2.09-1.4%$11.13+432.3%-51.3%$172.34M$153.73M-1.32240SGMTSagimet Biosciences2.3237 of 5 stars$5.60+27.6%$23.00+310.7%-8.0%$171.75M$2M0.008Gap UpHigh Trading VolumeCRBUCaribou Biosciences2.2043 of 5 stars$1.89-1.3%$10.20+441.1%-69.4%$170.69M$11.48M-1.16100Positive NewsTSVT2seventy bio2.2124 of 5 stars$3.30+0.9%$9.00+172.7%-7.1%$170.25M$100.39M-1.76440Positive News Related Companies and Tools Related Companies Kyverna Therapeutics Alternatives MediWound Alternatives Bright Minds Biosciences Alternatives Corbus Pharmaceuticals Alternatives Innate Pharma Alternatives Actuate Therapeutics Alternatives Sutro Biopharma Alternatives Sagimet Biosciences Alternatives Caribou Biosciences Alternatives 2seventy bio Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ALRN) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredVideo: Blindfolded Man Gets Into a Cybertruck… What Happens Next Will Shock You“Hi, I’m Jeff Brown… Even though I can’t see a thing… I’m about to get in this Cybertruck and drive up t...Brownstone Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aileron Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aileron Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
